Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand.

Préville X, Rittner K, Fend L.

Oncoimmunology. 2015 Feb 3;4(5):e1003013. eCollection 2015 May.

2.

Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.

Fend L, Gatard-Scheikl T, Kintz J, Gantzer M, Schaedler E, Rittner K, Cochin S, Fournel S, Préville X.

Cancer Immunol Res. 2014 Dec;2(12):1163-74. doi: 10.1158/2326-6066.CIR-14-0050. Epub 2014 Aug 28.

3.

Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.

Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, Sutter G, Kalinke U.

J Virol. 2007 Nov;81(22):12102-10. Epub 2007 Sep 12.

4.

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

Amato RJ.

Expert Opin Biol Ther. 2010 Feb;10(2):281-7. doi: 10.1517/14712590903586213. Review.

PMID:
20088718
5.

5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.

Amato RJ.

Expert Opin Biol Ther. 2007 Sep;7(9):1463-9. Review.

PMID:
17727334
6.
7.

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.

Bohnen C, Wangorsch A, Schülke S, Nakajima-Adachi H, Hachimura S, Burggraf M, Süzer Y, Schwantes A, Sutter G, Waibler Z, Reese G, Toda M, Scheurer S, Vieths S.

Allergy. 2013 Aug;68(8):1021-8. doi: 10.1111/all.12192. Epub 2013 Jul 30.

PMID:
23909913
8.

Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara.

Price PJ, Luckow B, Torres-Domínguez LE, Brandmüller C, Zorn J, Kirschning CJ, Sutter G, Lehmann MH.

J Virol. 2014 Sep;88(18):10840-50. doi: 10.1128/JVI.01524-14. Epub 2014 Jul 9.

9.

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M.

J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.

10.

Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.

Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B.

Cancer Immunol Immunother. 2001 Oct;50(8):397-407.

PMID:
11726134
11.
12.
13.

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara.

Meisinger-Henschel C, Schmidt M, Lukassen S, Linke B, Krause L, Konietzny S, Goesmann A, Howley P, Chaplin P, Suter M, Hausmann J.

J Gen Virol. 2007 Dec;88(Pt 12):3249-59.

PMID:
18024893
14.

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.

PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.

15.

Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.

Claudepierre MC, Hortelano J, Schaedler E, Kleinpeter P, Geist M, Remy-Ziller C, Brandely R, Tosch C, Laruelle L, Jawhari A, Menguy T, Marchand JB, Romby P, Schultz P, Hartmann G, Rooke R, Bonnefoy JY, Preville X, Rittner K.

J Virol. 2014 May;88(10):5242-55. doi: 10.1128/JVI.03819-13. Epub 2014 Feb 26.

16.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

17.

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.

Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB.

Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10.

18.

Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.

Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R.

J Immunother. 2009 Sep;32(7):765-72. doi: 10.1097/CJI.0b013e3181ace876.

PMID:
19561532
19.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

20.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.

Vaccine. 2007 Feb 9;25(8):1513-25. Epub 2006 Nov 7.

Supplemental Content

Support Center